Vigorous exercise does not appear to increase the risk of death or life-threatening arrhythmia for people with hypertrophic cardiomyopathy (HCM), according to a study supported by the National Institutes of Health. HCM is a rare, inherited disorder that causes the heart muscle to become thick and enlarged and affects 1 in 500 people worldwide. ItVigorous exercise does not appear to increase the risk of death or life-threatening arrhythmia for people with hypertrophic cardiomyopathy (HCM), according to a study supported by the National Institutes of Health. HCM is a rare, inherited disorder that causes the heart muscle to become thick and enlarged and affects 1 in 500 people worldwide. It » The FINANCIAL Health&Beauty
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known asA clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as » The FINANCIAL Health&Beauty
The FINANCIAL A far greater number of people around the world support women’s rights than many believe, reveals new research from NHH Norwegian School of Economics. According to Professor Alexander W. Cappelen, Deputy Director of The Centre of Excellence FAIR at NHH, and Professor Bertil Tungodden, Scientific Director of FAIR, a large global majorityThe FINANCIAL A far greater number of people around the world support women’s rights than many believe, reveals new research from NHH Norwegian School of Economics. According to Professor Alexander W. Cappelen, Deputy Director of The Centre of Excellence FAIR at NHH, and Professor Bertil Tungodden, Scientific Director of FAIR, a large global majority » The FINANCIAL Health&Beauty
The vaccine has been authorised in this new age group after it has been found to meet our standards of safety, quality and effectiveness, with no new safety concerns identified. This followed advice from the Commission on Human Medicines, which carefully reviewed the evidence. This is the second COVID-19 vaccine to be authorised in thisThe vaccine has been authorised in this new age group after it has been found to meet our standards of safety, quality and effectiveness, with no new safety concerns identified. This followed advice from the Commission on Human Medicines, which carefully reviewed the evidence. This is the second COVID-19 vaccine to be authorised in this » The FINANCIAL Health&Beauty